Community mobilization to modify harmful gender norms and reduce HIV risk: results from a community cluster randomized trial in South Africa

Introduction: Community mobilization (CM) is increasingly recognized as critical to generating changes in social norms and behaviours needed to achieve reductions in HIV. We conducted a CM intervention to modify negative gender norms, particularly among men, in order to reduce associated HIV risk. Methods: Twenty two villages in the Agincourt Health and Socio-Demographic Surveillance Site in rural Mpumalanga, South Africa were randomized to either a theory-based, gender transformative, CM intervention or no intervention. Two cross-sectional, population-based surveys were conducted in 2012 (pre-intervention, n = 600 women; n = 581 men) and 2014 (post-intervention, n = 600 women; n = 575 men) among adults ages 18 to 35 years. We used an intent-to-treat (ITT) approach using survey regression cluster-adjusted standard errors to determine the intervention effect by trial arm on gender norms, measured using the Gender Equitable Mens Scale (GEMS), and secondary behavioural outcomes. Results: Among men, there was a significant 2.7 point increase (Beta Coefficient 95% CI: 0.62, 4.78, p = 0.01) in GEMS between those in intervention compared to control communities. We did not observe a significant difference in GEMS scores for women by trial arm. Among men and women in intervention communities, we did not observe significant differences in perpetration of intimate partner violence (IPV), condom use at last sex or hazardous drinking compared to control communities. The number of sex partners in the past 12 months (AOR 0.29, 95% CI 0.11 to 0.77) were significantly lower in women in intervention communities compared to control communities and IPV victimization was lower among women in intervention communities, but the reduction was not statistically significant (AOR 0.53, 95% CI 0.24 to 1.16). Conclusion: Community mobilization can reduce negative gender norms among men and has the potential to create environments that are more supportive of preventing IPV and reducing HIV risk behaviour. Nevertheless, we did not observe that changes in attitudes towards gender norms resulted in desired changes in risk behaviours suggesting that more time may be necessary to change behaviour or that the intervention may need to address behaviours more directly. Clinical Trials number: ClinicalTrials.gov NCT02129530

Evaluating HIV/STD interventions in developing countries: do current indicators do justice to advances in intervention approaches?

HIV continues to spread unabated in many developing countries. Here we consider the interventions that are currently in place and critically discuss the methods that are being used to evaluate them as reported in the published literature. In recent years there has been a move away from highly individual-oriented interventions towards more participatory approaches that emphasise techniques such as community-led peer education and group discussions. However, this move towards more community orientated intervention techniques has not been matched by the development of evaluation methods with which to capture and explain the community and social changes which are often necessary preconditions for health-enhancing behaviour change. Evaluation research continues to rely on quantitative methodologies that fail to elucidate the complex changes that the newer interventions seek to promote within target communities. In addition, these methods of evaluation tend to rely on the use of highly individualistic and quantitative biomedical indicators such as HIV/STD rates, or knowledge, attitude, perception and behaviour (KAPB) survey questionnaires. We argue that such approaches are inadequate for the task of tracking and measuring important determinants of programme success such as psycho-social changes, features of the community-intervention interface and the degree of trust and identification with which members of target communities regard particular interventions. Rigorously conducted qualitative process evaluations taking account of the above factors could make a key contribution to the development of more successful HIV-prevention interventions

Margem de segurança do meloxicam em cães: efeitos deletérios nas células sangüíneas e trato gastrintestinal Margin of safety of meloxicam in dogs: deleterious effects on blood cells and gastrointestinal tract

Este trabalho investigou a margem de segurança do inibidor COX-2, meloxicam, em cães, enfocando seus efeitos deletérios nas células sangüíneas e no trato gastrintestinal. Para tanto, após uma avaliação clínico-laboratorial, os cães foram distribuídos nos seguintes grupos: I (placebo; n= 3), II (piroxicam; 1,0mg kg-1; n= 5), III (meloxicam; 0,2mg kg-1; n= 5), IV (meloxicam;1,0mg kg-1; n= 5) e V (meloxicam; 2,0mg kg-1; n= 5). Os fármacos foram usados, por via oral, por 16 dias. No 17&ordm; dia, repetiu-se o hemograma completo e, então, procedeu-se a eutanásia seguida pela necrópsia. No grupo I, não houve alterações dignas de nota. No grupo II, todos os cães apresentaram episódios moderados de vômito e diarréia. O perfil celular sangüíneo não foi significativamente modificado. Em dois cães, houve redução no hematócrito e na hemoglobina. Na necropsia, observaram-se focos hemorrágicos e lesões gastriduodenais moderadas. A análise microscópica revelou a presença de gastrite e enterite ulcerativa. No grupo III, quatro cães (80%) apresentaram vômito e diarréia, sem alteração no perfil celular sangüíneo. Na análise macroscópica, observaram-se lesões brandas na mucosa gástrica e focos hemorrágicos no duodeno em quatro cães. Na histopatologia, observaram-se lesões sugestivas de discreta gastroenterite. No grupo IV, os cinco cães tiveram vômito e diarréia sanguinolenta. Quatro deles (80%) apresentaram anemia (p < 0,05). Quatro e cinco cães apresentaram redução no hematócrito e hemoglobina, respectivamente. Ocorreram, ainda, leucocitose, neutrofilia e linfopenia significantes (p < 0,05), em 60% dos cães. Na necrópsia, evidenciaram-se hiperemia, hemorragia e úlceras gástricas severas em 100% dos animais. Verificou-se na microscopia um quadro de gastroenterite ulcerativa nos cinco cães. No grupo V, todos os cães apresentaram sérios episódios de vômito, diarréia e melena. Os quatro (80%) cães que suportaram o tratamento apresentaram anemia e leucocitose com neutrofilia e linfopenia significativas (p< 0,05). Houve, ainda, uma redução no hematócrito e hemoglobina desses cães. Na necropsia, foram visualizadas hemorragias e graves ulcerações gastroduodenais. À histopatologia, evidenciou-se severa gastroenterite. Conclui-se que o meloxicam, mesmo sendo COX-2 seletivo, induz efeitos deletérios no trato gastrintestinal e células sangüíneas de cães, quando administrado em concentrações cinco e dez vezes a dose terapêutica, que demonstram sua estreita margem de segurança nesta espécie.<br>This study investigated the margin of safety of the COX-2e inhibitor, meloxicam on blood cells and gastrointestinal tract of dogs. After a clinical and laboratorial examination, the dogs were distributed in the following groups: I (placebo; n=3), II (piroxicam: 1.0mg kg-1; n=5), III (meloxicam: 0.2mg kg-1; n=5), IV (meloxican: 1.0mg kg-1; n=5) and V (meloxican: 2.0mg kg-1; n=5). The drugs were given orally for 16 days. On the 17th day the complete hemogram was repeated and the euthanasia and necropsy were then accomplished. In group I there were no significative alterations. In group II, all the dogs showed moderate episodes of vomit and diarrhea. The blood-cell profile was not modified. Two dogs had hematocrit and hemoglobin reduction. In the necropsy, hemorrhagic spots and moderate gastroduodenal lesions were seen. The microscopic analysis revealed the presence of gastritis and ulcerative enteritis. In group III, four dogs (80%) showed vomit and diarrhea, without alteration in blood-cell profile. The microscopic analysis showed mild lesions in the gastric mucosa and hemorrhagic spots in the duodenum of four dogs. Histology showed lesions suggesting mild gastroenteritis. In group IV, all the dogs (n=5) showed vomit and blood diarrhea. Four of them showed anemia (p <0.05). Four and five dogs, respectively, had hematocrit and hemoglobin reduction. In addition, there was a significant (p<0.05) leukocytosis, neutrophilia and linfopenia in 60% of the dogs. The necropsy showed hiperemia, hemorrhage and severe gastric ulcers in all the dogs. In the microscopic analyses, gastroenteritis ulcerative was present in all the animals. In group V, the dogs (n=5) had serious vomit, diarrhea and melena episodes. The dogs that bore the treatment (n=4) had anemia and leukocytosis with neutrophilia and linfopenia significatives (p<0.05). All the dogs had hematocrit and hemoglobin reduction. In the necropsy, hemorrhages and severe gastroduodenal ulceration were seen. The microscopic analysis showed severe gastroenteritis. It can be concluded that, although meloxicam is a COX-2 selective inhibitor, it induces deleterious effects on gastrointestinal tract and blood cells of dogs, when given five or ten times the therapeutic dose, which demonstrate its low margin of safety in this animal specie